Creyon Bio

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible—on demand.

[Creyon Bio @creyonbio]

Creyon Bio announces a global licensing and R&D collaboration with @EliLillyandCo to develop RNA-targeted oligo therapies.

With our AI-Powered Oligo Engineering Engine, we’re accelerating novel drug design like never before. https://t.co/SswdYfSuqL #BiotechNews #AIinHealthcare

[Creyon Bio @creyonbio]

FDA is moving to reduce animal testing. For a while now, we’ve been in the fast lane to that goal. Our AI-powered platform enables smarter nucleic acid drug design with limited animal studies. The future of drug development is faster & more compassionate. https://t.co/i5UCdkNK4u

[Creyon Bio @creyonbio]

Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. https://t.co/SswdYfSuqL
#BiotechNews #AIinHealthcare

[Creyon Bio @creyonbio]

In September, we received our second U.S. patent for AI-powered RNA therapeutic development! Our approach achieves 80-90% success in creating safe compounds and makes development 100x more efficient. Transforming medicine through innovation.

https://t.co/7SNSa2XPpY

[Creyon Bio @creyonbio]

#ICYMI - Last month, we were granted our 2nd U.S. patent, which protects our proprietary AI/ML-enabled method for rapid engineering and optimization of therapeutic oligonucleotides.

Learn more in BioPharma Reporter's article: https://t.co/FgCHi7v1sv

#AIinHealthcare

[Creyon Bio @creyonbio]

Join us at the @OTSociety Meeting!

Sankha Pattanayak, Ph.D., will present on how sequence and chemistry collude to drive antisense oligo toxicity.

Learn how Creyon is advancing the field of OBMs through innovative research & AI-driven engineering.

https://t.co/KDEqls7H6K

[Creyon Bio @creyonbio]

Join our CEO, @chrihart, at @OGConferences Biologics US 2024 in San Diego!

He'll share insights on our AI-enabled platform for engineering oligonucleotide-based medicines, showcasing how we're transforming discovery to engineering.

https://t.co/XAIAfdbwGE

[Creyon Bio @creyonbio]

Our COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept 25, discussing AI in pharma.

He'll share how our platform decodes rules for safer, quicker OBM development and how we moved from concept to clinic in just one year.
https://t.co/6eH1H3zo6c

[Creyon Bio @creyonbio]

Creyon's COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept. 25 discussing how our platform is engineering drugs for safety first with the goal of efficiently creating "best-in-class" oligo medicines that will minimize side effects.

[Creyon Bio @creyonbio]

Our CEO @chrihart is at #MedInvest2024!

Learn about how our #AI platform decodes rules for safer, quicker OBM development, overcomes delivery challenges with targeted aptamers, and has recently translated into positive#clinical outcomes.

https://t.co/dW1aWW7koT

[Creyon Bio @creyonbio]

Our CEO @chrihart is presenting at #MedInvest2024! Discover how we're engineering OBMs 100x more efficiently and learn about our AI-driven platform that's overcoming delivery challenges with targeted aptamers, transforming treatments for diseases.

https://t.co/bbErsoYxto

[Creyon Bio @creyonbio]

Our CEO @chrihart latest article in @Bio_Insights explores the future of oligonucleotide-based medicines (OBMs).
OBMs are fundamentally programmable drugs and modern AI/ML techniques could help resolve this challenge with purpose-built data.
Learn more: https://t.co/GmlqFnCwX3

[Creyon Bio @creyonbio]

We're officially welcoming Shaquille Vayda @Lux_Capital, to Creyon's Board of Directors!

Shaq’s diverse experience spanning technology, aerospace and life sciences aligns well with our innovative approach to drug engineering.

https://t.co/vyGfVl3WWO

[Creyon Bio @creyonbio]

Please welcome Serge Messerlian @DCVC, to our Board of Directors!

With extensive leadership in life sciences, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of OBMs.

https://t.co/G2EFkMro3k

[Creyon Bio @creyonbio]

Exciting news! Creyon has been granted another U.S. patent, which protects our proprietary AI/ML-enabled method for rapid engineering and optimization of therapeutic oligonucleotides.

Read our press release to learn more: https://t.co/QBXMZ3ase9

#AIinHealthcare

[Creyon Bio @creyonbio]

2/2: Dr. Coufal was critical in helping Creyon push the first allele selective LNA ASO into the clinic as part of an individualized antisense oligonucleotide therapy in collaboration with the TNPO2 Foundation.

https://t.co/aZKkp2IRwJ

@NINDSDiversity

[Creyon Bio @creyonbio]

1/2: Congratulations Dr. Nicole Coufal for receiving the Landis Award for Outstanding Mentorship from the @NIH_NINDS!

[Creyon Bio @creyonbio]

Our CEO @chrihart will join a roundtable discussion at the #RNALeaders Congress on the delivery of small RNA therapeutics.

At Creyon Bio, we're reinventing oligonucleotide-based medicines through our innovative approach to drug development.

Join us: https://t.co/QZPfyS8gqJ

[Creyon Bio @creyonbio]

Tune into part 3 of our CMO David Dimmock's interview with @CGT_Live about the Creyon Platform & what's on the horizon at Creyon through 2025. We look forward to advancing more drugs into clinical trials for common disease indications.

Watch here: https://t.co/dWi85jREhn

[Creyon Bio @creyonbio]

Check out part 2 of our CMO David Dimmock's interview with @CGT_Live about our work using AI to engineer an antisense #oligo for a patient with an ultra-rare disease.

https://t.co/GJ1KiLW2Tj